Crossmark

Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling

Crossref DOI link: https://doi.org/10.1007/s00228-019-02640-1

Published Online: 2019-02-07

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boons, Christel C. L. M. https://orcid.org/0000-0003-0202-3612
Timmers, Lonneke

Janssen, Jeroen J. W. M.

Swart, Eleonora L.

Hugtenburg, Jacqueline G.

Hendrikse, N. Harry
Funding

Funding for this research was provided by:

Novartis (CAMN107ENL04T)
License Information

Text and Data Mining valid from 2019-02-07
More Information

Article History

Received: 10 December 2018

Accepted: 25 January 2019

First Online: 7 February 2019

Compliance with ethical standards

:

: J.J.W.M. Janssen is an advisory board member for Abbvie, Incyte, Jazz Pharmaceuticals, and Pfizer and has received research support funding from Novartis and Bristol Myers Squibb and speaker’s fees from Incyte and Pfizer. The other authors declare no conflict of interest.

: The study was approved by the Medical Ethics review board of Amsterdam University Medical Centers (location VUmc, Amsterdam) (2013.035), as well as the ethical boards of each participating center. All procedures performed were in accordance with the ethical standards of the Medical Ethics review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.